TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES

1 . A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising:

administering a composition to the mammalian body, wherein the composition comprises

taurultam and taurinamide in a weight ratio of 1 taurultam:7 taurinamide.

2 .- 4 . (canceled)

5 . The method according to claim 1 further comprising administering the composition in conjunction with an oncolytic agent and/or radiotherapy.

6 .- 13 . (canceled)

14 . The method according to claim 1 wherein the composition further comprises methylene glycol.

15 .- 18 . (canceled)

19 . The method according to claim 1 wherein the dosage range for taurultam is from 5 mg/kg to 280 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.

20 . The method according to claim 19 wherein the dosage range for taurultam is from 5 mg/kg to 40 mg/kg, combined with taurinamide with a dosage range of from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.

21 . The method according to claim 19 wherein the composition is administered in conjunction with an oncolytic agent.

22 . (canceled)

23 . The method according to claim 14 wherein the dosage range for taurultam is from 5 mg/kg to 280 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.

24 . The method according to claim 23 wherein the dosage range for taurultam is from 5 mg/kg to 40 mg/kg, combined with taurinamide with a dosage range of from 35 mg/kg to 40 mg/kg, combined with methylene glycol with a dosage range of from 5 mg/kg to 40, from once daily through weekly, for an effective period of time based on individual patient response.

25 . The method according to claim 23 wherein administering the composition further comprises administering the composition in conjunction with an oncolytic agent and/or radiotherapy.

26 . The method according to claim 1 wherein administering the composition comprises delivering the composition to a patient using one from the group consisting of parenteral delivery, intramuscular delivery and intravenous delivery.

27 . The method according to claim 1 wherein the composition is included in a nanoparticle, and further wherein the nanoparticle is configured to delay exposure of the composition until the nanoparticle reaches the site of a tumor.

28 . The method according to claim 27 wherein the nanoparticle comprises a core of the composition and an exterior coating, wherein the exterior coating is configured to prevent exposure of the composition prior to arrival of the nanoparticle at the site of the tumor.

29 . The method according to claim 28 wherein the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.

30 . The method according to claim 1 wherein administering the composition comprises delivering the composition using a polymer system which is configured to delay premature degradation of the composition.

31 . The method according to claim 30 further comprising pegylating the composition using polyethylene glycols (PEGs) to delay premature degradation of the composition.

32 . The method according to claim 1 wherein the composition further comprises at least one from the group consisting of taurolidine, taurultam, taurinamide and methylene glycol.